EA 7426 "Pathophysiology of Injury-Induced Immunosuppression" (Université Claude Bernard Lyon 1 - Hospices Civils de Lyon - bioMérieux), Joint Research Unit HCL-bioMérieux, Immunology Laboratory and Anesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, 5 place d'Arsonval, 69003, Lyon Cedex 03, France.
Anesthesiology and Critical Care Medicine, Edouard Herriot Hospital, Hospices Civils de Lyon, 69003, Lyon, France.
Crit Care. 2024 Jul 15;28(1):240. doi: 10.1186/s13054-024-04990-4.
The immune response of critically ill patients, such as those with sepsis, severe trauma, or major surgery, is heterogeneous and dynamic, but its characterization and impact on outcomes are poorly understood. Until now, the primary challenge in advancing our understanding of the disease has been to concurrently address both multiparametric and temporal aspects.
We used a clustering method to identify distinct groups of patients, based on various immune marker trajectories during the first week after admission to ICU. In 339 severely injured patients, we initially longitudinally clustered common biomarkers (both soluble and cellular parameters), whose variations are well-established during the immunosuppressive phase of sepsis. We then applied this multi-trajectory clustering using markers composed of whole blood immune-related mRNA.
We found that both sets of markers revealed two immunotypes, one of which was associated with worse outcomes, such as increased risk of hospital-acquired infection and mortality, and prolonged hospital stays. This immunotype showed signs of both hyperinflammation and immunosuppression, which persisted over time.
Our study suggest that the immune system of critically ill patients can be characterized by two distinct longitudinal immunotypes, one of which included patients with a persistently dysregulated and impaired immune response. This work confirms the relevance of such methodology to stratify patients and pave the way for further studies using markers indicative of potential immunomodulatory drug targets.
危重病患者(如脓毒症、严重创伤或大手术患者)的免疫反应是异质且动态的,但人们对其特征及其对预后的影响知之甚少。到目前为止,推进我们对疾病认识的主要挑战一直是同时解决多参数和时间方面的问题。
我们使用聚类方法,根据 ICU 入院后第一周内各种免疫标志物轨迹,识别不同的患者群体。在 339 名严重受伤的患者中,我们最初对常见生物标志物(可溶性和细胞参数)进行了纵向聚类,这些标志物在脓毒症免疫抑制阶段的变化已得到充分证实。然后,我们使用由全血免疫相关 mRNA 组成的标志物应用这种多轨迹聚类。
我们发现,这两组标志物都揭示了两种免疫类型,其中一种与较差的预后相关,例如增加医院获得性感染和死亡率的风险,以及延长住院时间。这种免疫类型表现出过度炎症和免疫抑制的迹象,并且随着时间的推移持续存在。
我们的研究表明,危重病患者的免疫系统可以通过两种不同的纵向免疫类型来描述,其中一种包括持续存在失调和受损免疫反应的患者。这项工作证实了这种方法在对患者进行分层以及为潜在免疫调节药物靶点标志物的进一步研究铺平道路方面的相关性。